期刊
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
卷 62, 期 4, 页码 646-654出版社
MOSBY-ELSEVIER
DOI: 10.1016/j.jaad.2009.05.030
关键词
adalimumab; alefacept; clinical trials; efalizumab; etanercept; infliximab
类别
资金
- Galderma Laboratories LP
Pyoderma gangrenosum is a rare and often painful skin disease that can be unpredictable in its response to treatment. There is currently no gold standard of treatment or published algorithm for choice of therapy. The majority of data comes from case studies that lack a standard protocol not only for treatment administration but also for the objective assessment of lesion response to a specific therapy. This review provides an update to the treatment of pyoderma gangrenosum with a particular focus on new systemic therapies. (J Am Acad Dermatol 2010:62:646-54.)
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据